Over 6,000 cases of popular ice cream brand recalled over ‘life-threatening' allergen
A popular brand of ice cream, Breyers, has recalled one of its flavors following customer concerns that there was a mislabeling error.
On Tuesday, the United States Food and Drug Administration (FDA) confirmed in a report that 6,668 cases of Breyers Chocolate Truffle Ice Cream were voluntarily recalled by Unilever Manufacturing on June 2 after it was found that the tubs actually contained Rocky Road ice cream.
The Chocolate Truffle flavor has an allergen label that reads, 'may contain tree nuts,' while the Rocky Road flavor declares almonds as one of the ingredients.
The cause for the recall was determined to be 'undeclared allergens and mislabeled product.'
The recall was classified as Class II, which the organization describes as a 'situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.'
It was not listed where the affected ice cream was sold, as the FDA's report only states the ice cream was distributed to 'distribution centers and retail locations across the U.S.'
In a statement made to People, a representative for Breyers said, 'People with an almond allergy should not consume the product due to risk of serious or life-threatening allergic reaction. The safety and quality of our products are our top priority. For more information, consumers can visit www.breyers.com or call 1-800-931-2826.'
The recall comes a few weeks after Wells Enterprises, also known as Wells Dairy, issued a voluntary recall of 22 different types of ice cream and frozen yogurt treats.
The Iowa-based company initiated the nationwide recall on April 25, citing the possible 'presence of plastic' in more than 17,000 tubs of its products.
An enforcement report, published by Wells Enterprises, lists an assortment of products from 103 distribution centers affected by the recall. The items have an expiration date ranging between March and October 2026.
The flavor most affected by the issue is its Vanilla Frozen Yogurt, which includes 5,280 recalled tubs.
The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed.
Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from foodborne illnesses in 2023.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
43 minutes ago
- The Hill
Medically tailored nutrition can help make America healthy
Chronic disease is a threat not only to Americans' physical health but also to the nation's financial health. Conditions like heart disease, cancer, diabetes and kidney failure account for trillions of dollars in annual health care spending and are among the leading causes of death in the U.S. The growing consensus is clear that our health care system needs better solutions to manage chronic diseases. One promising tool is surprisingly simple: food. But not just any food. We need nutritious, locally sourced, medically tailored meals — food-based interventions designed by registered dietitian nutritionists specifically for chronically ill Americans. These medically tailored meals are proven to improve health outcomes, reduce hospitalizations and lower health care costs. Just as important, they can reduce patients' dependency on medications, making health care more effective and affordable. At the Boston-based nonprofit I lead, we have seen firsthand how medically tailored meals can transform lives. One of our clients, for example, reduced his daily medications from 14 to just four after enrolling in our program. This is what we mean when we say 'food is medicine' — food, either alone or in conjunction with pharmaceuticals, can help patients become and stay healthier. These meals are not only about nourishment. They are about addressing the root causes of chronic diseases while offering real cost savings. Medically tailored meals prioritize nutrition, treating the underlying causes of disease, not just symptoms. They reduce dependence on medication, leading to fewer prescriptions and better health outcomes. These meals prioritize fresh ingredients over processed foods, with a commitment to quality local food. They lead to immediate cost savings, with reductions in hospitalizations and medical costs. And they support local businesses, strengthening local farms and fishing industries through prioritization of regional sourcing. Does it work? The evidence is clear. Studies published in JAMA and Health Affairs show that medically tailored meals reduce hospitalizations by 49 percent and emergency room visits by 70 percent. They have also been shown to lower total medical costs by a remarkable 16 percent. Another recent study published in Health Affairs estimates that a nationwide rollout of medically tailored meals could save $32 billion annually. In a time of policy uncertainty, one thing is clear: 'Food is medicine' is a bipartisan opportunity to transform health care. The Make America Healthy Again movement is dedicated to reducing the burden of chronic diseases, decreasing reliance on pharmaceuticals and integrating nutrition into health care. The Senate MAHA Caucus is already focused on improving access to high-quality, nutrient-dense foods and addressing the root causes of disease. Congress should act now to expand medically tailored nutrition for veterans, older Americans and people with disabilities — groups who stand to benefit the most. Let us seize this moment and make medically tailored nutrition a central part of making America healthy again. David B. Waters is the CEO of Community Servings, a Boston-based nonprofit provider of medically tailored meals and nutrition services, and founder of the AMPL Institute.


New York Times
an hour ago
- New York Times
The F.D.A. Is Reviewing Infant Formula for the First Time in Decades
Last week, the Food and Drug Administration convened a panel of nutrition scientists, pediatricians and other experts to discuss the first comprehensive review of infant formula nutrient requirements since 1998. The review is part of an initiative, called 'Operation Stork Speed,' which health secretary Robert F. Kennedy Jr. announced in March to improve the safety and quality of the U.S. infant formula supply. Many health experts have applauded the effort, but some also worry that it could raise unnecessary fears that infant formulas in the United States are unsafe. In a Fox News segment last Friday, Dr. Marty Makary, the F.D.A. commissioner, implied that common ingredients in formulas, like seed oils, may be harmful to health, mentioning them alongside contaminants with known health effects like lead and arsenic. 'Moms want baby formula without seed oils, without corn syrup, without added sugar, without arsenic and lead and other heavy metals,' Dr. Makary said in the segment. We asked several scientists who specialize in infant health and nutrition to weigh in on four concerns Dr. Makary and other F.D.A. officials have raised about infant formulas in the United States. These products are safe, they said, but there are ways to make them better. Want all of The Times? Subscribe.


Indianapolis Star
an hour ago
- Indianapolis Star
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older. 'RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV.' While the risk of RSV is well recognized in infants and older adult populations, adults aged 18-59 years with chronic conditions are also vulnerable. 1 Over one-third of adults aged 18-59 years have at least one underlying condition that puts them at increased risk of severe RSV disease, 2 with disease burden and hospitalization rates in this population being comparable, or even exceeding, that observed in older adults. 3 This approval was supported by results from Moderna's Phase 3 study (NCT06067230), which evaluated the safety and immunogenicity of mRESVIA in adults aged 18-59 with underlying health conditions. The immune responses against both RSV-A and RSV-B met prespecified non-inferiority immunobridging criteria when compared to those observed in adults aged 60 years and older in the pivotal Phase 3, placebo-controlled safety and efficacy study. Comparable levels of neutralizing antibodies were observed across both the 18-49 and 50-59 age subgroups, supporting the vaccine's consistent immunogenicity profile in this at-risk, younger adult population. These findings were presented at the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) meeting in April 2025 and have been published in Clinical Infectious Diseases. The vaccine was generally well-tolerated, and the most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. Moderna intends to have mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the U.S. for the 2025-2026 respiratory virus season. About mRESVIA® (Respiratory Syncytial Virus Vaccine) mRESVIA® is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna COVID-19 vaccines. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. mRESVIA® is a registered trademark of Moderna. INDICATION mRESVIA is a vaccine to protect you against lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV). mRESVIA is for people 60 years of age and older and also for people 18 through 59 years of age who are at increased risk for RSV (people with medical conditions such as diabetes or with diseases affecting the lungs and heart). Vaccination with mRESVIA may not protect all people who receive the vaccine. mRESVIA does not contain RSV. mRESVIA cannot give you lower respiratory tract disease caused by RSV. IMPORTANT SAFETY INFORMATION Who should not get mRESVIA? You should not get mRESVIA if you had a severe allergic reaction to any ingredient in mRESVIA. What should you tell your healthcare provider? Tell your healthcare provider about all of your medical conditions, including if you: Have any allergies Had a severe allergic reaction after receiving a previous dose of any other vaccine Have a fever Have a bleeding disorder or are on a blood thinner Are immunocompromised or are on a medicine that affects your immune system Have received any other RSV vaccine Have ever fainted in association with an injection How is mRESVIA given? mRESVIA is given as an injection into the muscle. What are the risks of mRESVIA? There is a very small chance that mRESVIA could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of mRESVIA. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction may include: Trouble breathing Swelling of your face and throat A fast heartbeat A rash all over your body Dizziness and weakness Side effects that have been reported in clinical trials with mRESVIA include: Injection-site reactions: pain, underarm swelling or tenderness in the same arm of the injection, swelling (hardness), and redness Fatigue, headache, muscle pain, joint pain, chills, nausea or vomiting, fever and hives These may not be all of the possible side effects of mRESVIA. Ask your healthcare provider about any side effects that concern you. You may report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or Please click for mRESVIA Full Prescribing Information. Moderna Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mRESVIA; the disease burden associated with RSV, particularly in adults with certain risk factors; and the availability of mRESVIA for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Chris Ridley Head of Global Media Relations +1 617-800-3651 Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 1 Prasad N, Walker TA, Waite B, et al. Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions. Clin Infect Dis 2021; 73(1): e158-e63. 2 Wilker E, Jiang M, Francis B, et al. Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States. Poster presented at: ESCMID; April 2025; Vienna, Austria. 3 Weycker D, Averin A, Houde L, et al. Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infect Dis Ther 2024; 13(1): 207-20. SOURCE: Moderna, Inc.